Can the timing of a hormone test make a difference? Yes, day 3 of the menstrual cycle is considered an important window for ...
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the ...
After months of global uncertainty, market sentiment is beginning to improve as several macroeconomic factors turn supportive. Lower crude oil prices, easing currency pressure, hopes of global trade ...
The biggest stories of the day delivered to your inbox.